论文部分内容阅读
[目的]探讨恩度静脉滴注联合介入化疗栓塞治疗中晚期肝癌的临床疗效。[方法]本文将48例原发性肝癌患者随机分为观察组和对照组,其中观察组采用恩度静脉滴注联合介入化疗栓塞治疗,并与单独采用介入化疗栓塞治疗的对照组进行临床疗效比较。[结果]恩度联合TACE治疗肝癌的总有效率和AFP转阴率均较单纯采用TACE治疗的对照组高,差异有统计学意义(P﹤0.05)。恩度能有效抑制TACE术后肿瘤缺血缺氧引起的VEGF水平上升,抑制肿瘤血管生成,降低肿瘤的复发和转移,提高TACE治疗肝癌的疗效。另外,两组的不良反应相似,未出现心律失常、心电图改变、鼻出血等与恩度治疗相关副作用。[结论]恩度静脉滴注联合介入化疗栓塞治疗中晚期肝癌是一有效的治疗方法,值得在临床中推广和进一步研究。
[Objective] To investigate the clinical effect of Endu intravenous infusion combined with chemotherapy and embolization in the treatment of advanced liver cancer. [Methods] Forty-eight patients with primary liver cancer were randomly divided into observation group and control group. The observation group was treated with Endo intravenous drip combined with interventional chemotherapy and embolization, and was compared with the control group treated with interventional chemoembolization alone Compare [Results] The total effective rate of Adeno combined with TACE in treatment of hepatocellular carcinoma and the rate of AFP negative conversion were higher than those in the control group treated with TACE only, with statistical significance (P <0.05). Endurance can effectively inhibit the tumor after TACE hypoxia-induced VEGF levels rise, inhibit tumor angiogenesis, reduce tumor recurrence and metastasis and improve the efficacy of TACE in the treatment of liver cancer. In addition, two groups of adverse reactions are similar, no arrhythmia, ECG changes, epistaxis and Endocrine related side effects. [Conclusion] Endo intravenous infusion combined with chemotherapy and embolization in the treatment of advanced hepatocellular carcinoma is an effective treatment, which is worth to be popularized and further studied in clinic.